title: Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection.
abstract: Clear cell (cc) renal cell carcinoma (RCC) is the most common type of cancer found in the kidney accounting for ~90% of all kidney cancers. In 2012, there were ~337,000 new cases of RCC diagnosed worldwide with an estimated 143,000 deaths, with the highest incidence and mortality in Western countries. Despite improvements in cancer control achieved with VEGF- and mTOR-targeted therapy for RCC, progression remains virtually universal and additional therapies are needed. The pivotal results of the METEOR trial led to cabozantinib's designation as a breakthrough drug by the US Food and Drug Administration and its approval for treatment of advanced RCC in 2016. Subsequent data from the CABOSUN trial, where caboxantinib is compared with sunitinib, will provide information on the relative activity of cabozantinib as first-line therapy for ccRCC. We review the development of cabozantinib in advanced RCC and its role in the treatment landscape for advanced RCC.
authors.affiliation: Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
authors.forename: Steven S
authors.initials: SS
authors.lastname: Yu
authors.affiliation: Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
authors.forename: David I
authors.initials: DI
authors.lastname: Quinn
authors.affiliation: Division of Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
authors.forename: Tanya B
authors.initials: TB
authors.lastname: Dorff
keywords: cabozantinib; clear cell carcinoma; kidney cancer; renal cell carcinoma; tyrosine kinase inhibitor